PTAB challenges

Proceedings overview

One active Inter Partes Review (IPR) proceeding is on file for US patent 9005293, with a status of "Trial Instituted". This means that the patent owner will need to defend the challenged claims, and the outcome will significantly impact the patent's defensive posture.

IPR2025-01598 — Medtronic, Inc. v. Ahmnon D. MOSKOWITZ et al

• Type: Inter Partes Review
• Filed: 2025-09-29
• Status: Trial Instituted – The PTAB has determined that there is a reasonable likelihood that at least one of the challenged claims is unpatentable, and a trial has been formally initiated.
• Judge panel: Not yet public.
• Petition grounds: Not yet public.
• Institution decision: Instituted – Date not yet public, but the status indicates institution has occurred. The reasoning is not yet public.
• Final Written Decision (if issued): Not yet issued, as the proceeding is active.
• Settlement / termination: Not yet settled or terminated.
• Appeal: Not applicable at this stage, as no Final Written Decision has been issued.
• Defensive value: This active IPR presents a potential opportunity to challenge the patentability of claims in US9005293. A defendant facing assertion of this patent should closely monitor this proceeding, as a successful challenge could invalidate asserted claims, weakening the patent owner's position.

Strategic summary

As of today, 2026-05-24, there is one active Inter Partes Review (IPR) proceeding, IPR2025-01598, on US patent 9005293. This proceeding was filed by Medtronic, Inc. and has reached the "Trial Instituted" stage, meaning the PTAB has authorized a trial to determine the patentability of the challenged claims. The specific claims challenged, the prior art asserted, and the panel's reasoning for institution are not yet publicly available in the provided data.

Given that the IPR is still in its early stages (post-institution, pre-Final Written Decision), no claims of US9005293 have been canceled or sustained through this proceeding. All claims of the patent remain legally in force unless and until a Final Written Decision invalidates them. The estoppel landscape will only become relevant after a Final Written Decision is issued. At that point, Medtronic, Inc. and its privies would be barred from raising any ground that was raised or reasonably could have been raised during the IPR. Until then, potential defendants are not estopped from raising any prior art grounds. The involvement of Medtronic, Inc. as a petitioner suggests a significant interest in challenging the patent, and Unified Patents' tracking of this litigation suggests potential aggregator involvement.

Recommended next steps

For a defendant facing assertion of US9005293, the primary next step is to closely monitor IPR2025-01598. While the specific details of the petition grounds and institution decision are not yet public in the provided data, a trial has been instituted, indicating a viable challenge to at least some claims.

• The PTAB has a statutory 1-year trial deadline from institution. The institution date is not explicitly provided, but given the filing date of 2025-09-29 and a "last modified" date of 2026-04-03, the Final Written Decision would likely be due in late 2026 or early 2027.
• Review the publicly available documents for IPR2025-01598 on the USPTO PTAB E2E system to determine the specific claims challenged, the prior art references relied upon by Medtronic, Inc., and the PTAB's reasoning for instituting the trial. This information is crucial for understanding the potential impact on your defensive strategy. (A direct link cannot be provided without the full PTAB E2E URL, but it can be found by searching for "IPR2025-01598" on the USPTO PTAB E2E portal).